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A NOVEL ASSOCIATION BETWEEN SERUM BILIRUBIN LEVELS 
 
AND AGE-RELATED MACULAR DEGENERATION 
 
SUDHEER AKELLA 
ABSTRACT 
 The purpose of this study is to examine the association between serum 
bilirubin and the development of age-related macular degeneration (AMD). The 
study design includes the utilization of a USA-nationally representative population 
based cross-sectional study in the National Health and Nutrition Examination 
Survey: specifically, the NHANES III and continuous NHANES from years 2005-2008. 
15,501 survey participants from the NHANES studies chosen for this analysis were 
interviewed for demographic, behavioral, and medical information, put through a 
comprehensive medical examination segment, and a laboratory analysis portion. 
The 15,501 participants were chosen based on their age (40 and above) and the 
presence of fundus photographs. Fundus photographs were graded using 
standardized protocol to diagnose early and later AMD, which were combined to 
form the outcome “AMD” in a binary variable. Serum bilirubin levels were measured 
using spectrophotometry. Of the 15,501 participants in the study, 1305 (8.9%) were 
diagnosed with AMD. In a multivariate logistic regression adjusted for age, sex, 
smoking status, race, and serum C-reactive protein (CRP) levels, bilirubin was 
significantly associated with AMD (odds ratio, 0.728; confidence interval, 0.547–
  v
0.969; P value, 0.0296). The findings of this study indicate that the antioxidative 
effects of bilirubin may play protective role in the pathology of AMD. 
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INTRODUCTION 
Age-related macular degeneration (AMD) 
Age-related macular degeneration (AMD) is a leading cause of blindness 
worldwide and progresses with 
deterioration of retinal structure 
(Jager, Mieler, & Miller, 2008; 
Lim, Mitchell, Seddon, Holz, & 
Wong, 2012). AMD affects about 
1.75 million people in the United 
States, while about 7 million are 
at risk to contract the condition 
(Ding, Patel, & Chan, 2009). 
Patients with age-related 
macular degeneration typically 
present with a loss of central 
vision, as shown in Figure 1. 
AMD is correlated with 
Figure 1: Loss of visual acuity due to AMD. A) Two children as seen with normal 
eyes. B) Identical view of children as A, but as seen with AMD eyes. Note that 
most vision loss occurs centrally, with some peripheral vision loss.  
Reproduced with permission from 
http://www.nei.nih.gov/photo/keyword.asp?conditions=Age-
Related+Macular+Degeneration+%28AMD%29&match=all. 
A 
B 
  
progressive vision loss, since the 
significantly over time if left un
method of reducing permanent vision loss, knowledge of risk factors and detection 
of early manifestations of AMD is crucial to preserving vision in the United States’ 
growing elderly population. 
Figure 2: Structure of bilirubin.
structure of bilirubin including hydrogen bonds (dotted lines). Note the structural 
change and lack of free hydrogen molecules in 
Reproduced with permission 
http://commons.wikimedia.org/wiki/File:Structure_of_bilirubin.png 
http://commons.wikimedia.org/wiki/File:Bilirubin_H_bonded.svg.
A 
B 
2 
likelihood is high that the symptoms will worsen
treated. As prevention of AMD is the most effective 
 
 
Bilirubin 
 Bilirubin is an 
endogenous compound formed 
as the main end product in the 
breakdown of the red blood cells, 
among other sources 
1959). Bilirubin, although once 
considered metabolic waste, is 
known to have a specific set of 
antioxidative effects in the body 
(Perlstein, Pande, Creager, 
 A) Linear structure of bilirubin. 
B, rendering it hydrophobic.
from 
 
(Schmid, 
B) Physiological 
 
and 
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Weuve, & Beckman, 2008). In Figure 2, bilirubin is shown in both its linear form 
and physiological form, in which it forms a three-dimensional structure via 
hydrogen bonding. As a result of hydrogen bonding within the structure of bilirubin, 
it lacks free atoms for hydrogen bonding with water, deeming the molecule 
hydrophobic (Fevery, 2008).  
 
Specific Aims/Objectives 
While bilirubin is known to be a powerful antioxidant, it has yet to be shown 
to have an effect on the development of AMD. Given that oxidative stress is an 
established risk factor for age-related macular degeneration (Jager, Mieler, & Miller, 
2008), it may be advantageous to determine any possible association between 
serum bilirubin levels and AMD.  
 Using the National Health and Nutrition Examination Survey (NHANES), a 
nationally representative cross-sectional examination of the United States 
population, the goal of this study is to test the hypothesis that serum bilirubin is 
protective for AMD. More specifically, we aim to 
 
(1) Associate lower serum bilirubin levels with the symptoms and 
diagnosis of age-related macular degeneration. 
(2) Examine the effect of antioxidant behavior of bilirubin within the 
association. 
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(3) Discuss the possibility of using 
analogs of bilirubin in the treatment of AMD. 
 
An association between higher 
bilirubin levels and lowered risk of AMD may 
allow for earlier detection of at-risk patients 
for AMD, supplement the understanding of 
the pathology of AMD, and offer insight that 
may help guide future therapies for AMD. 
 
Normal retinal structure 
In order to comprehend the 
pathological underpinnings of AMD, it is 
important to first understand the structure 
and function of the normal retina. The 
The Normal Retina. 
Figure 3: The structure of the normal retina. A) Fundus photograph including 
the retina and macula (encircled in black). B) Histological view of the retina 
including macular photoreceptors (black arrow), retinal pigment epithelium 
(white arrow), and choroid (red arrow). C) Spectral-domain Ocular Coherence 
Tomography of the normal retina, including the macula (encircled in white), 
fovea (blue arrow), RPE (white arrow), Bruch’s membrane (yellow arrow), outer 
plexiform layer (orange arrow), and choroid (red arrow). 
Reproduced with permission from Age-Related Macular Degeneration (Jager, 
Mieler, & Miller, 2008), Copyright Massachusetts Medical Society 
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unaffected retina, shown in Figure 3, contains the macula centrally and posteriorly. 
Within the macula lies the fovea centrally. The outer plexiform later, the retinal 
pigment epithelium (RPE), Bruch’s membrane, and the choroid, are collectively 
responsible for the supply of nutrients to the macula, and together form the blood-
ocular barrier. Because the macula is dense in photoreceptors, it is attributed to 
high-resolution visual acuity corresponding to facial recognition, reading, and 
observation of fine details (Jager, Mieler, & Miller, 2008). With age, however, certain 
changes to the retinal structure have been known to be clinically associated with the 
onset of age-related macular degeneration.  
 
Classification of AMD 
The initial cautionary marker for diagnosis of age-related macular 
degeneration is subretinal, extracellular deposits of glycoproteins and lipids called 
“drusen” that can be found in the peripheral retina (Jager, Mieler, & Miller, 2008; 
Ding, Patel, & Chan, 2009). Two morphological forms of drusen have been 
established: hard and soft. Hard drusen are characterized by a smaller size, 
yellowish appearance and are found in people with or without age-related macular 
degeneration. Soft drusen are noted to be pale in comparison, larger and more 
diffused, and with blurry edges (Ding, Patel, & Chan, 2009). The Age-Related Eye 
Disease Study (AREDS), funded by the National Institute of Health (NIH), has 
employed a drusen severity scale to classify the presence and severity of age-related 
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macular degeneration based on the symptoms observed (Davis et al., 2005). The 
classification of AMD is performed using stereoscopic color fundus photographs on 
the basis of four features (Jager, Mieler, & Miller, 2008; Davis et al., 2005):  
 
(1) The size and area of combined drusen and increased pigment,  
(2) The amount of depigmentation of the retinal pigment epithelium,  
(3) The extent of atrophy of the retinal pigment epithelium and 
photoreceptors, and 
(4) The presence of formation of new blood vessels in the choroid, termed 
choroidal neovascularization. 
 
 AREDS’ classification system of age-related macular degeneration includes 
four categories of AMD (See Table 1) (Lim, Mitchell, Seddon, Holz, & Wong, 2012). 
Early AMD presents as a few small hard drusen (Lim, Mitchell, Seddon, Holz, & 
Wong, 2012). Intermediate AMD corresponds with multiple drusen, and/or 
abnormalities in the pigmentation of the retinal pigment epithelium, called 
hypopigmentation or hyperpigmentation (Jager, Mieler, & Miller, 2008; Lim, 
Mitchell, Seddon, Holz, & Wong, 2012). Hypopigmentation is the loss of pigment in 
the RPE, and is an observable measure of the loss of cellular function within the RPE 
(Ding, Patel, & Chan, 2009). Once early AMD progresses to diagnosis, there are two 
main classifications of the condition: dry AMD and wet AMD. On the other hand, 
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hyperpigmentation occurs peripherally to hypopigmentation, as the retinal pigment 
epithelium attempts to compensate for cell death (Ding, Patel, & Chan, 2009). Dry 
AMD is characterized by geographic atrophy, the death of cells in the macula (Lim, 
Mitchell, Seddon, Holz, & Wong, 2012). In advanced dry AMD, geographic atrophy 
spreads to the center of the macula including the fovea (Jager, Mieler, & Miller, 
2008; Lim, Mitchell, Seddon, Holz, & Wong, 2012). Wet AMD, which is sometimes 
referred to as choroidal neovascular age-related macular degeneration, includes the 
formation of new blood vessels in the choroid and the buildup of subretinal fluid, 
which may eventually lead to further damage of the retina beyond AMD (Jager, 
Mieler, & Miller, 2008; Lim, Mitchell, Seddon, Holz, & Wong, 2012; Davis et al., 
2005).  
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Table 1: AREDS Classification of AMD. 
Category Name Drusen frequency 
and size Description 
1 Early AMD Few, less than 63 
µm in diameter Hard drusen 
2 Intermediate AMD 
Multiple, less than 
63 µm in diameter; 
Few, between 65 
and 124 µm in 
diameter 
Soft drusen; Abnormalities in the 
pigmentation of the retinal pigment 
epithelium (hypopigmentation or 
hyperpigmentation) 
3 Dry AMD 
Multiple, between 
63 and 124 µm in 
diameter; 
At least one, 
greater than or 
equal to 125 µm in 
diameter 
Soft drusen; Geographic atrophy of the 
macula, excluding the fovea 
4 
Advanced 
Dry AMD 
Multiple, between 
63 and 124 µm in 
diameter; 
At least one, 
greater than or 
equal to 125 µm in 
diameter 
Soft drusen; Geographic atrophy 
extending into the fovea, or central 
geographic atrophy 
Wet AMD 
Multiple, between 
63 and 124 µm in 
diameter; 
At least one, 
greater than or 
equal to 125 µm in 
diameter 
Soft drusen; Choroidal 
neovascularization, the formation of 
new blood vessels branching from the 
choroid; Subretinal fluid 
  
Retinal Imaging 
There are multiple modalities utilized to image the retina. In this study, the 
imaging methods used are 
ocular coherence tomography (OCT), and fluorescein angiography (FA). While 
Figure 4: AREDS Categories of AMD through fundus photographs
stage (Category 1) AMD as seen by few small drusen (< 63 
Intermediate AMD (Category 2) as seen by many small drusen and few 
intermediately sized drusen (between 63 and 124 
stage dry AMD (Category 3), with large drusen (< 124
present among small and intermediate drusen. 
choroidal neovascular lesion (encircled in black). 
Reproduced with permission
http://www.nei.nih.gov/p
Related+Macular+Dege
 
A 
C 
9 
fundography (Figure 3, Figure 4), spectra
μm; blue arrows). 
μm; green arrows). 
 μm; yellow arrows) 
D) Neovascular AMD, signified by 
 
 from 
hoto/keyword.asp?conditions=Age-
neration+%28AMD%29&match=all. 
B 
D 
 
l-domain 
. A) Early-
B) 
C) Late-
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fundography images the retina as seen on indirect ophthalmoscopy (Figure 3A), 
OCT depicts a cross-sectional image of the retinal layers (Figure 3C), and FA 
(Figure 5B, 5C) investigates the integrity and perfusion dynamics of the retina. All 
three technologies, which require dilation of the pupil to fully observe the retina, 
offer diagnostic information that is crucial to differential diagnosis.  
 
1. Fundography 
Photographs of the fundus (Figure 3A) are obtained by means of a fundus 
camera, which essentially consists of an indirect ophthalmoscope as well as a 
camera. Viewing the retina through an indirect ophthalmoscope allows for the 
medical professional to observe and analyze the size of drusen. Additionally, the 
physician is able to assess whether drusen are hard or soft, depending on the edges 
and color of drusen present (Jager, Mieler, & Miller, 2008). As opposed to simply 
viewing the retina through indirect ophthalmoscopy, fundography offers an image 
that can be saved and viewed at any time, without the need for repeated dilation of 
pupils.  
 
2. Spectral-domain Ocular Coherence Tomography 
Spectral-domain OCT is unique in that it captures a cross-sectional image of 
the retina and its components. A cross-sectional view contains information that is 
not viewable using indirect ophthalmoscopy. OCT’s cross-sectional imaging 
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provides the physician with a perspective of retinal architecture that includes the 
macula, the fovea, the choroid, the retinal pigment epithelium, and Bruch’s 
membrane, whereas in ophthalmoscopy, only the superficial structures of the retina 
can be viewed. Furthermore, OCT allows the physician to noninvasively assess and 
analyze the physiological behavior of the blood-ocular barrier, as well as any 
abnormalities in the thickness of various retinal components that may be difficult to 
observe using ophthalmoscopy or fundography (Jager, Mieler, & Miller, 2008).  
  
3. Fluorescein Angiography 
While the utilization of fundography to determine the severity of AMD is 
widespread, it is mainly beneficial in observing qualities of drusen. Fluorescein 
angiography is an adapted form of fundography that involves the intravenous 
injection of sodium fluorescein into the patient’s circulation. Due to the fluorescent 
nature of the compound, fluorescein is observed throughout retinal vasculature, 
using a fundus camera. A series of images of the retina are captured and time-
stamped by the fundus camera, allowing the filling of fluorescein dye in the blood 
vessels of the retina to be observed by the physician. Furthermore, FA has the 
potential to promote clinical examination of lesions formed as a result of choroidal 
neovascularization (Jager, Mieler, & Miller, 2008). Because the perfusion of the 
fluorescein dye throughout the vasculature is time-dependent, a hyperfluorescence 
is present in earlier frames, as late leakage of the dye occurs in later frames of 
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images with choroidal 
neovascularization (Figure 5B and 5C) 
(Jager, Mieler, & Miller, 2008). 
 
Pathology of AMD 
The pathologic progression of 
age-related macular degeneration, 
while not wholly understood, is known 
to be brought about by demographic, 
behavioral, and genetic factors (Lim, 
Mitchell, Seddon, Holz, & Wong, 2012; 
Figure 5: Neovascular AMD. A) 
Fundus photograph including 
neovascularization (white arrow). B) 
Early frame in a series of images using 
FA, showing early fluorescence of 
neovascularization (blue arrow). C) 
Late frame in a series of images using 
FA, showing late fluorescence of 
neovascularization (red arrow). Note 
the larger diameter of fluorescence 
when compared with part B, indicating 
that more time has passed. D) OCT 
cross-sectional image of a neovascular 
AMD retina, present with subretinal 
fluid (white arrow).  
Reproduced with permission from Age-
Related Macular Degeneration (Jager, 
Mieler, & Miller, 2008), Copyright 
Massachusetts Medical Society. 
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Ding, Patel, & Chan, 2009). With senescence comes a change in the retinal structure. 
These changes may affect the size and shape of cells of the retinal pigment 
epithelium, the thickness of Bruch’s membrane, and/or the neuronal activity in the 
retina (Ding, Patel, & Chan, 2009). Although the presence of a few small drusen is 
often unremarkable in people over the age of 50 years, early-stage AMD is 
considered when soft drusen begin to grow high in frequency and increase in size 
(see Table 1) (Ding, Patel, & Chan, 2009). As drusen increase in size and are 
classified as soft drusen, they have a higher ability to incur both hypopigmentation 
and hyperpigmentation of the retinal pigment epithelium, which has been known to 
have a strong association with macular degeneration (Ding, Patel, & Chan, 2009). 
Although both forms of drusen are known to be composed of an array of 
inflammatory molecules, immunoglobulins, and glycoproteins, the mechanistic 
functionality in which they further the progression of age-related macular 
degeneration has yet to be elucidated (Ding, Patel, & Chan, 2009). 
One direct effect of old age is the loss of cells in the retinal pigment 
epithelium, which is responsible for hypopigmentation and eventual peripheral 
hyperpigmentation in the RPE (Ding, Patel, & Chan, 2009). The RPE, a part of the 
blood-ocular barrier, plays an elemental role in the supply of nutrients to 
photoreceptor cells in the macula. As the cells of the RPE deteriorate, macular 
photoreceptors undergo a loss of function. With the degradation of photoreceptors 
in the macula comes the loss of central vision.  
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As AMD progresses from early to late-stage, the hypopigmentation in the 
retinal pigment epithelium is manifested in an oval shape peripherally outlined by 
hyperpigmentation, an observation tied to geographical atrophy (Ding, Patel, & 
Chan, 2009). The degeneration of both the photoreceptors in the macula and RPE 
cells leads to a thinning of the overall retina, further impairing vision (Ding, Patel, & 
Chan, 2009).  
In the more common form of late-stage wet AMD, neovascularization that 
roots from the choroid extends through Bruch’s membrane into the subretinal 
space, leading to the development of a layer of fibrovascular membrane that lies 
among the blood-ocular barrier (Ding, Patel, & Chan, 2009). As a result of the 
formation of new blood vessels, excess serous fluid leaks from neovascular 
membranes into the outer plexiform layer of the retina (Ding, Patel, & Chan, 2009). 
In rare instances of late-stage wet age-related macular degeneration, the 
angiogenesis present in the subretinal space originates from the neurosensory 
retina, and is labeled as retinal angiomatous proliferation (RAP) (Ding, Patel, & 
Chan, 2009). 
On a molecular level, the pathological progression of age-related macular 
degeneration is partially attributable to genetic mutation. Specifically, single 
nucleotide polymorphisms of genes associated with responses to oxidative stress, 
angiogenesis pathways, and inflammatory response, among others are proven to 
affect the onset and progression of early, intermediate, and advanced age-related 
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macular degeneration, based on the presence of certain markers found in drusen 
(Jager, Mieler, & Miller, 2008; Lim, Mitchell, Seddon, Holz, & Wong, 2012).  
Oxidative proteins have been found at a higher rate in drusen from AMD eyes 
when compared to drusen obtained from normal eyes (Crabb et al., 2002). These 
oxidative proteins are believed to be a result of oxidation by reactive oxygen species 
(ROS) (Crabb et al., 2002). Reactive oxygen species are molecules in which the 
oxygen atom contains an unpaired election (Beatty, Koh, Phil, Henson, & Boulton, 
2000). ROS molecules include free radicals, hydrogen peroxide, and singlet oxygen 
(Beatty, Koh, Phil, Henson, & Boulton, 2000). Oxidation, in general, is cumulative 
with aging. In addition, there is an increase in the age related effects of cytotoxic 
oxidative damage by ROS molecules (Beatty, Koh, Phil, Henson, & Boulton, 2000). 
Smoking, aging, irradiation, inflammation, and pollutants have shown to 
significantly increase the level of ROS in the body, leading to an increase in oxidative 
damage (Beatty, Koh, Phil, Henson, & Boulton, 2000). Specifically, the retina is highly 
susceptible to damage from oxidative stress for a few reasons. First, tissue in the 
retina consumes more oxygen than any other bodily tissue (Beatty, Koh, Phil, 
Henson, & Boulton, 2000). Secondly, short-wavelength light has been shown to 
induce further oxidative damage to the retina (Beatty, Koh, Phil, Henson, & Boulton, 
2000). Furthermore, photoreceptors in the macula are mainly composed of 
polyunsaturated fatty acids, which are highly susceptible to oxidation by ROS 
(Beatty, Koh, Phil, Henson, & Boulton, 2000). The oxidation of polyunsaturated fatty 
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acids is known to initiate a cytotoxic chain reaction of oxidations, further damaging 
the macula (Beatty, Koh, Phil, Henson, & Boulton, 2000). The unique structure and 
function of the retina lends itself to be damaged readily with age, by means of 
oxidative stress. As a result, there is believed to be a strong relation between the 
effects of oxidation and age-related macular degeneration. 
A single nucleotide polymorphism identified as Tyr402His (substitution of 
tyrosine with histidine at amino acid 402) of the CFH gene on chromosome 1 
(located at 1q31) increases the risk of AMD by a factor of 2.1 to 4.6 in whites (Jager, 
Mieler, & Miller, 2008; Ding, Patel, & Chan, 2009). CFH codes for complement factor 
H (CFH), an elemental inhibitory factor of the complement system of the immune 
response, normally synthesized in the macula and present in the retinal pigment 
epithelium as well as the choroid (Jager, Mieler, & Miller, 2008; Ding, Patel, & Chan, 
2009). Specifically, complement factor H inhibits the alternative pathway of the 
innate immune system by acting as a cofactor, binding to C3b thus inhibiting its 
breakdown (Yu et al., 2007). Due to the Tyr402His single nucleotide polymorphism, 
signs of a decrease in inhibitory activity of complement factor H are present in 
patients with AMD (Jager, Mieler, & Miller, 2008; Ding, Patel, & Chan, 2009). Because 
elevated levels of components of the complement system at the specific step of 
inhibitory action of CFH are found in drusen, it has been inferred and proven that 
the genetic mutation of CFH is a risk-incurring single nucleotide polymorphism for 
AMD (Jager, Mieler, & Miller, 2008; Ding, Patel, & Chan, 2009). The Tyr402His 
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variant form of complement factor H is found in about half of all patients diagnosed 
with AMD, demonstrating an association between the polymorphism of CFH and the 
progression of maculopathy (Hageman et al., 2005). 
Complement factor H contains short consensus repeats (SCRs), and the 
Tyr402His mutation in variant CFH is located at the seventh repeat, SCR7 (Yu et al., 
2007). Additionally, the SCR7 repeat is known to play a crucial role in the binding of 
complement factor H to C-reactive protein (CRP), a systemic inflammatory marker 
(Yu et al., 2007). In a comparison between Tyr402His and Tyr402Tyr variants of 
complement factor H, many functionalities of the complement factor were found to 
be similar or identical, yet the binding of the two variant forms of CFH to CRP at 
SCR7 was found to be much higher in the Tyr402Tyr variant CFH than the 
Tyr402His single nucleotide polymorphism type of CFH that is associated with AMD 
(Ding, Patel, & Chan, 2009). Furthermore, serum levels of C-reactive protein have 
been shown to be elevated with statistical significance in patients with intermediate 
and advanced age-related macular degeneration (Seddon JM, Gensler G, Milton RC, 
Klein ML, & Rifai N, 2004). It is believed that as a result of dysfunctional CFH and its 
inability to bind CRP, an increase in CRP levels in the choroid follows (Ding, Patel, & 
Chan, 2009). Another theory states that the Tyr402His variant CFH no longer 
illustrates its inhibitory effect on the alternative pathway of the immune response, 
leading to a chronic increase in inflammatory response, eventually leading to a 
surge in the serum C-reactive protein levels in the retina affected by AMD (Ding, 
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Patel, & Chan, 2009). Although without clear knowledge of the mechanism, there is, 
with little doubt, a strong correlation among the single nucleotide polymorphic 
complement factor H, C-reactive protein, and the nature of inflammatory response 
that is detected in patients diagnosed with age-related macular degeneration. 
 
Risk factors for AMD 
Consistently throughout epidemiological research of AMD, three risk factors 
have consistently been shown to be associated with the onset of age-related macular 
degeneration: age, smoking status, and racial background.  
 
1. Age 
The most evident risk factor for AMD is the age of the individual. In a pooled 
study (N=14,752) comprised of three separate population-based studies of racially 
similar populations in Europe, North America, and Australia, about 13% of the 
population 85 years or older suffer from AMD, whereas only 0.2% of participants 
between the ages 55 to 64 years were diagnosed with the condition (Smith et al., 
2001). Similar trends were found when AMD was split into the dry and wet forms. 
Additionally, no AMD was found in participants with the ages of 54 years and below 
(Smith et al., 2001). By using racially homogenous groups of participants (the 
participants had roots of origin in northern Europe), the pooled study further 
pinpoints the effect on AMD that age exhibits (Smith et al., 2001). The aging patient, 
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as reviewed above, has an increased accumulation of oxidation throughout the 
retinal structure, leading to the formation of drusen and the increased likelihood of 
AMD.  
 
2. Smoking 
In the pooled population-based study from three continents, smoking 
tobacco was found to be another risk factor for developing AMD. Current smokers 
were more likely to have AMD over nonsmokers (odds ratio, 3.11; confidence 
interval, 2.10–4.63) (Smith et al., 2001; Friedman, Katz, Bressler, Rahmani, & 
Tielsch, 1999). Former smokers were more likely to develop AMD over nonsmokers 
(odds ratio, 1.34; confidence interval, 0.96–1.87), indicating the reduction in risk of 
AMD with smoking cessation (Smith et al., 2001). In addition, participants who were 
considered current smokers were even further associated with diagnosis of 
neovascular AMD (odds ratio, 4.55; confidence interval, 2.74–7.54) yet still strongly 
associated with geographic atrophy (odds ratio, 2.56; confidence interval, 1.26–
5.20) (Smith et al., 2001). It is important to note that of the well-known and 
observed risk factors, smoking is the sole preventable risk factor for age-related 
macular degeneration, as it is considered a behavioral risk factor rather than genetic 
or demographic. As mentioned in a previous section, cigarette smoking has an effect 
on AMD progression by increasing the oxidative load on the smoker’s body.   
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3. Race 
Racial background has been shown to extensively contribute as a risk factor 
of age-related maculopathy. The Baltimore Eye Survey composed of 5308 blacks and 
whites aged 40 years or older from East Baltimore, showed that Caucasian 
background increases risk for developing AMD (odds ratio, 4.1; confidence interval, 
1.4–11.6) (Friedman, Katz, Bressler, Rahmani, & Tielsch, 1999). While the presence 
of small drusen (less than or equal to 64 μm) was nearly equivalent (20.3% of 
whites and 19.9% of blacks were diagnosed with small drusen), the difference in 
presence of large drusen (greater than 125 μm) among participants over 70 years 
old was statistically significant (15.2% of whites and only 9% of blacks) (Friedman, 
Katz, Bressler, Rahmani, & Tielsch, 1999). One proposed reason as to why race is 
considered a risk factor for AMD deals with genetic mutation. It is believed that the 
single nucleotide polymorphism corresponding to Tyr402His that alters CFH, which 
codes for complement factor H, is more prevalent in whites than other races (Ding, 
Patel, & Chan, 2009).  
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Bilirubin metabolism 
While the majority of heme exists as part of hemoglobin in erythrocytes, it 
can also be found in a host of cytochrome P450 enzymes as well as in myoglobin 
(Schmid, 1959). Heme, which exists in a porphyrin ring structure with a chelated 
Figure 6: Heme catabolism. Heme is degraded into biliverdin, a reaction 
catalyzed by heme oxygenase that releases an iron and a monoxide, opening its 
ring structure. Biliverdin is reduced to bilirubin, catalyzed by biliverdin 
reductase, with nicotinamide adenine dinucleotide phosphate (NADPH) and 
nicotinamide adenine phosphate (NADH) as reducing agents.  
Reproduced from https://www.urmc.rochester.edu/labs/Maines-
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iron at the center, is degraded into bilirubin in macrophages present in the spleen 
and bone marrow, as well as Kupffer cells in the liver (Fevery, 2008).  
Initially, heme oxygenase catalyzes the cleavage of the α carbon of heme, 
leading to the release of the chelated iron and a carbon monoxide molecule, and the 
formation of biliverdin, a precursor to bilirubin (Fevery, 2008). Biliverdin is then 
reduced, a reaction catalyzed by biliverdin reductase, thus forming bilirubin, which 
is then secreted into plasma (Figure 6) (Fevery, 2008). The resulting structure 
(Figure 2B) no longer contains free atoms for hydrogen bonding with water in 
plasma, rendering bilirubin hydrophobic. 
 Due to its hydrophobicity, bilirubin is highly dependent on the binding 
capabilities of albumin in plasma for transportation (Schmid, 1959). Bilirubin bound 
to albumin is referred to as unconjugated bilirubin, is transported to the liver, 
where it is converted to conjugated bilirubin by a series of reactions in hepatocytes 
(Fevery, 2008). Conjugation of bilirubin is characterized by the addition of 
glucuronic acid by means of an ester linkage with either one or two sugars, forming 
either monoconjugated or diconjugated bilirubin (Fevery, 2008). The esterification 
of glucuronic acid is catalyzed by uridine diphosphate-glucuronyltransferase (UDP-
GT) and leads to a conformational change of bilirubin, opening up the structure by 
discarding the hydrogen bonding that exists in unconjugated bilirubin (Schmid, 
1959). As a result, conjugated bilirubin achieves hydrophilicity and is thus freely 
transported in blood plasma without the aid of albumin binding (Schmid, 1959). 
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Transport of conjugated bilirubin from hepatocytes into the plasma is active and 
mediated by multidrug resistance-related protein, an adenosine triphosphate 
(ATP)-binding cassette transporter (Fevery, 2008). 
 
Antioxidative effects of bilirubin 
 Antioxidant molecules are crucial in maintaining the balance of production 
and elimination of reactive oxygen species (Jansen & Daiber, 2012). While the 
strong antioxidative effects of bilirubin have long been known, the method in which 
it achieves such effect has only been proposed more recently. Biliverdin is reduced 
to bilirubin by biliverdin reductase; on the other hand, it has been proposed that 
bilirubin is oxidized to biliverdin by lipophilic ROS (Figure 7) (Jansen & Daiber, 
2012). In turn, as a part of the breakdown of heme, biliverdin is again reduced by 
biliverdin reductase into bilirubin, forming a redox amplification cycle between 
biliverdin and bilirubin (Jansen & Daiber, 2012). By reacting with ROS, bilirubin, as 
well as other antioxidants, successfully removes the potential downstream effect of 
the ROS. As bilirubin accepts oxidation, ROS no longer has the ability to initiate a 
series of cytotoxic chain reactions. While the mechanism has not been proven, the 
antioxidative effects of the biliverdin-bilirubin system have been shown to be 
concentration dependent (Jansen & Daiber, 2012). Additionally, the biliverdin-
bilirubin system has been strongly associated with endothelial cell protection from 
oxidative stress (Jansen et al., 2010). Furthermore, evidence of heme oxygenase 
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playing a contributory role in the oxidative effect of the bilirubin-biliverdin system 
has been shown (Jansen et al., 2010). In the proposed redox amplification cycle, 
heme oxygenase is responsible for the oxidation of heme to form biliverdin from 
heme. While a large amount of evidence seems to show that the proposed cycle is in 
fact the methodology in which bilirubin is the strongest endogenous antioxidant in 
the human body, the direct link has yet to be proven.  
 
Bilirubin and AMD 
 Among research pertaining to age-related macular degeneration and 
oxidative stress, the main focus has been on the administration of antioxidative 
supplements to slow down the progression of AMD. Furthermore, some research 
has been dedicated to the mechanism in which oxidative stress affects the retina and 
AMD. However, little to no research can be found regarding the strongest 
antioxidant produced endogenously, bilirubin, and the oxidative causes of AMD. As 
the primary aim of this study is to associate bilirubin and its antioxidative effects to 
the onset and progression of AMD through utilization of a nationally representative 
NHANES group of survey participants, it is important to outline the causative 
mechanisms that may be disrupted by bilirubin. The presence of drusen is the initial 
symptom of macular degeneration, and is a result of oxidative stress on the retina. 
To associate the serum bilirubin levels as protective against AMD means indicating 
that bilirubin plays a role in protection of retinal oxidation. 
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Figure 7: Proposed redox amplification cycle of bilirubin and biliverdin. As 
previously shown, heme is metabolized into biliverdin and, ultimately, bilirubin 
by heme oxygenase and biliverdin reductase. The redox amplification includes 
oxidation of bilirubin into biliverdin, protecting tissue from cytotoxic chain 
reactions of oxidation by reactive oxygen species.  
Reproduced with permission from “Direct antioxidant properties of bilirubin and 
biliverdin. Is there a role for biliverdin reductase?” (Jansen & Daiber, 2012). 
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METHODS 
Study Design 
 The National Health and Nutrition Examination Survey (NHANES), conducted 
by the National Center for Health Statistics (NCHS) and the Centers for Disease 
Control and Prevention (CDC), is a cross-sectional conglomerate of studies 
performed to assess national health statistics (“NHANES 2005 - 2006,” n.d.). The 
NHANES is conducted using a nationally representative sample of participants, 
weighted to better represent national statistics. The NHANES is a comprehensive 
survey, composed of a physical exam, an interview portion, and laboratory testing. 
In this study, data from the NHANES III and the continuous NHANES (from subsets 
2005-2006 and 2007-2008), including serum bilirubin levels, diagnosis of age-
related maculopathy based on fundus photographs, smoking status, racial 
background, age, sex, and serum C-reactive protein levels of survey participants 
were used to evaluate the proposed association (“NHANES 2005 - 2006,” n.d.). Data 
corresponding to a total of 15,501 participants in the three studies were utilized to 
examine the association in this study.  
 
Serum Bilirubin level 
 To determine serum bilirubin levels of survey participants, blood plasma 
samples were treated with a strongly acidic (pH 1-2) diazo reagent (“NHANES 2005 
- 2006,” n.d.; “NHANES III,” n.d.; “NHANES 2007 - 2008,” n.d.). Due to its reactivity 
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with acidic diazo groups, bilirubin was converted into azobilirubin. As the reaction 
progresses, the absorbance of the sample is altered (“NHANES 2005 - 2006,” n.d.). 
By measuring the change in absorbance at 520 nm of the sample using fixed-time 
intervals by spectrophotometry, the concentration of bilirubin can be determined. 
The change in absorbance is proportional to the concentration of bilirubin in the 
sample. In the NHANES III Survey, the Hitachi Model 737 was used to measure the 
change in absorbance of the sample. In the 2005-2006 portion, as well as in 2007 (of 
the 2007-2008 continuous NHANES), the Beckman Synchron LX20 was used, while 
in 2008 (of the 2007-2008 continuous NHANES), the Beckman Coulter UniCel 
DxC800 was used to measure the change in absorbance of the serum sample. The 
sensitivity for this technique was reported as 0.1 mg/dL (“NHANES 2005 - 2006,” 
n.d.; “NHANES III,” n.d.; “NHANES 2007 - 2008,” n.d.). In this study, serum bilirubin 
levels were used in two variables: a continuous variable of bilirubin, and an ordinal 
variable stratified into quartiles (less than or equal to 0.4 mg/dL, between 0.4 
mg/dL and 0.6 mg/dL, between 0.6 and 0.7 mg/dL, and greater than 0.7 mg/dL).  
  
AMD and grading using fundus photographs  
 In all of the NHANES surveys used in this study, the diagnosis AMD was 
stratified into three groups: no AMD, early AMD, and late AMD (“NHANES 2005 - 
2006,” n.d.; “NHANES III,” n.d.; “NHANES 2007 - 2008,” n.d.). The categorical 
analysis of the presence of AMD was conducted using fundus photographs of 
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participants’ worse eye. No AMD corresponds to survey participants who lacked the 
presence of drusen. Early AMD denotes that the fundus photograph of the survey 
participant indicated the presence of drusen and pigmentary abnormalities in the 
retinal pigment epithelium. Late AMD is assigned to participants’ fundus 
photographs that indicated geographic atrophy of the macula and/or quantitative 
signs of exudative macular degeneration (“NHANES 2005 - 2006,” n.d.; “NHANES 
III,” n.d.; “NHANES 2007 - 2008,” n.d.). In this study, the outcomes “early AMD” and 
“late AMD” were combined to form a binary variable. Fundus photographs were 
taken by trained technologists and graded by nine reviewers using protocols set 
forth by the NCHS. In the NHANES III Survey, the Canon CR4-45NM non-mydriatic 
fundus camera, while the Canon CR6-45NM non-mydriatic fundus camera was used 
in the continuous NHANES (“NHANES 2005 - 2006,” n.d.; “NHANES III,” n.d.; 
“NHANES 2007 - 2008,” n.d.). An infrared video camera was used in a darkened 
room to supplement the fundus cameras for natural pupil dilation, as to avoid the 
need for dilating drops. Survey participants with bilateral blindness (visual acuity 
lacking light perception vision in both eyes), eye infection, or eye patches on both 
eyes did not undergo retinal imaging and were excluded from this study (“NHANES 
2005 - 2006,” n.d.; “NHANES III,” n.d.; “NHANES 2007 - 2008,” n.d.). Additionally, 
participants aged 40 years and older underwent retinal imaging, while those under 
40 were also excluded from this portion of the NHANES examination. For the 
purposes of this study, the AMD variable was stratified into a binary variable based 
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on whether the survey participant was diagnosed with either the lack of AMD or the 
presence of AMD.  
 
Co-variables 
 As this study includes a multivariate logistic regression analysis, the co-
variables used included age, sex, race, smoking status, and serum C-reactive protein 
levels. While age was coded as a continuous variable, sex, smoking status, and race 
were considered binary. Smoking status, a part of the interview portion of the 
NHANES studies, was stratified into two outcomes: current or past smoker, or non-
smoker. Participants considered current or past smokers had answered yes to 
either the question “Have you smoked at least 100 cigarettes in your life?” and/or 
“Do you now smoke cigarettes?” (“NHANES 2005 - 2006,” n.d.; “NHANES III,” n.d.; 
“NHANES 2007 - 2008,” n.d.). On the contrary, non-smokers answered no to both 
questions. Race, although normally considered a categorical variable, was 
restructured as a binary variable: white, or non-white. Serum CRP levels was treated 
as a continuous variable, measured in milligrams per deciliter using latex-enhanced 
nephelometry (“NHANES 2005 - 2006,” n.d.; “NHANES III,” n.d.; “NHANES 2007 - 
2008,” n.d.). In NHANES III, latex particles coated with rabbit anti-CRP antibodies 
were added to serum samples of participants, forming antigen-antibody complexes 
(“NHANES III,” n.d.). Mouse monoclonal anti-CRP antibodies were added to serum 
samples in the continuous NHANES (“NHANES 2005 - 2006,” n.d.; “NHANES 2007 - 
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2008,” n.d.). Light scattering measured by a Behring nephelometer after 6 minutes is 
proportional to the concentration of CRP in the sample, calculated using a 
calibration curve (“NHANES 2005 - 2006,” n.d.; “NHANES III,” n.d.; “NHANES 2007 - 
2008,” n.d.).   
 
Statistical Analysis 
 Because the aim of NHANES is to produce nationally representative health 
statistics, it is necessary to incorporate weighted statistical analysis when using 
NHANES datasets. Using weighted statistical analysis allows for compensation for 
over-selection in certain subgroups and to reduce variances in the estimation 
procedure with high accuracy (“NHANES 2005 - 2006,” n.d.; “NHANES III,” n.d.; 
“NHANES 2007 - 2008,” n.d.). High accuracy was achieved by estimating weights 
through estimates provided in the Census Bureau of the United States. In this study, 
Statistical Analysis System (SAS; SAS Institute, Cary, NC, USA) was used to perform 
t- and χ2 test procedures to assess the association. Multivariate logistic regressions 
were used to estimate the odds ratios of serum bilirubin level association with AMD, 
adjusted for age, sex, race, smoking status, and serum CRP levels co-variably. The 
analysis of serum bilirubin association with AMD was performed with both 
continuous levels of bilirubin and bilirubin levels stratified into quartiles.   
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RESULTS 
 In this study, a total of 15,501 participants of NHANES were analyzed to 
examine the association between bilirubin and AMD. Of the 15,501 participants, 
1305 (8.9%) were diagnosed with AMD, while the fundus photos of 13,439 (91.1%) 
lacked any signs of AMD. A close to equal distribution between men (7525; 48.5%) 
and women (7976; 51.5%) was determined. Furthermore, an indirect relationship 
between serum bilirubin levels and the diagnosis of AMD was exhibited. 
 Table 2 presents the characteristics of 15,501 participants in the study, 
striated into quartiles by serum bilirubin level. Notably, the level of bilirubin is 
higher in participants who were non-smokers when compared to smokers. A similar 
inverse trend is found between bilirubin and CRP levels. Additionally, more women 
had lower serum bilirubin than men.  
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Table 2: Characteristics of NHANES Participants Stratified by Age 
 Serum Bilirubin Level in mg/dL (%) 
 
Characteristic 
 
≤ 0.4 
(n=4208) 
  0.4 - 0.6 
(n=2601) 
 0.6 - 0.7  
(n=4435) 
 
> 0.7 
(n=4257) 
 
Total 
(n=15501) 
AMD     
 
  
   Yes 354 (9.9) 214 (9.5) 322 (8.0) 350 (8.8) 1305 (8.9) 
   No 
3229 
(90.1) 
2033 
(90.5) 
3717 
(92.0) 
3621 
(91.2) 
13439 
(91.1) 
      
Sex     
 
  
   Female 
2680 
(63.7) 
1267 
(48.7) 
1883 
(42.5) 
2146 
(50.4) 
7976 (51.5) 
   Male 
1528 
(36.3) 
1334 
(51.3) 
2552 
(57.5) 
2111 
(49.6) 
7525 (48.5) 
      
Race     
 
  
   White 
2665 
(63.3) 
1719 
(66.1) 
2889 
(65.1) 
2849 
(66.9) 
10122 
(65.3) 
   Non-white 
1543 
(36.7) 
881 (33.9) 
1546 
(34.9) 
1408 
(33.1) 
5378 (34.7) 
      
Smoking Status     
 
  
   Current or 
   past smoker 
2081 
(49.5) 
1221 
(53.1) 
1894 
(42.7) 
1539 
(36.2) 
6735 (43.4) 
   Non-smoker 
2127 
(50.5) 
1380 
(46.9) 
2541 
(57.3) 
2718 
(63.8) 
8766 (56.6) 
    
 
  
Mean (SD) 
   
  
Age      
 
60.1 
(13.6) 
61.2 (13.6) 
61.0 
(13.3) 
61.2 (13.2) N/A 
C-reactive protein      
      
(mg/dL) 
0.64 
(1.06)  
 0.49 
(0.90) 
0.47 
(0.83) 
0.42 (0.86) N/A 
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Table 3 indicates a statistically significant association between serum level 
of bilirubin and the diagnosis of AMD. With an odds ratio of 0.728, bilirubin is 
shown to be protective against the onset and progression of AMD using data from 
15,501 NHANES survey participants. Statistical significance is achieved as the P 
value equates to 0.0296, as the association is adjusted for age, sex, race, smoking 
status, and C-reactive protein in serum. Stratified bilirubin (into quartiles) was 
additionally found to associate inversely with AMD with statistical significance 
(odds ratio, 0.923; confidence interval, 0.851–1.000; P value, 0.0490). Age (odds 
ratio, 1.071; confidence interval, 1.061–1.081; P value, <0.0001), and race (odds 
ratio, 1.369; confidence interval, 1.123–1.667; P value, 0.0018) were found to be risk 
factors for AMD with statistical significance, in compliance with past research. 
Smoking (odds ratio, 1.120; confidence interval, 0.959–1.308) and CRP levels (odds 
ratio, 1.054; confidence interval, 0.930–1.194) were determined to be potential risk 
factors, lacking statistical significance.   
 
Table 3: Association of AMD with Serum Bilirubin Levels 
 OR (95% CI) P value 
Total Serum Bilirubin a 0.728 (0.547-0.969) 0.0296 
a
 Analysis stratified for age, sex, race, smoking status, and serum levels of CRP. 
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DISCUSSION 
 
 The increasing incidence and prevalence of age-related macular 
degeneration, due to increased longevity, calls for the betterment of care with 
regards to AMD. Given that AMD has a high potential to incur irreversible blindness, 
it is increasingly beneficial to improve research efforts for AMD. This study has 
successfully associated serum bilirubin content with age-related macular 
degeneration using a nationally representative dataset, adjusting for age, sex, race, 
smoking status, and serum CRP levels. Equipped with the finding that the 
antioxidative effects of bilirubin may play a role in defense against drusen formation 
and progression of AMD, it is essential to discuss how to this information can be 
used to accelerate AMD research and treatment.  
Prophylaxis against AMD is minimal, as oxidation is a naturally occurring 
phenomenon in the human body, and the effect of the risk factors of age and race are 
unavoidable, due to their demographic nature. Because smoking is a well-known 
risk factor for AMD, smokers are encouraged to quit smoking and non-smokers are 
recommended to never smoke to slow its progression. Furthermore, dietary intake 
has been shown to affect AMD onset. In the AREDS study, analysis of dietary intake 
showed that the antioxidants lutein, zeaxanthin, and β-carotene were shown to 
reduce the risk of AMD (Lim, Mitchell, Seddon, Holz, & Wong, 2012). As macular 
carotenoids, these molecules have been shown to reduce the impact of oxidative 
stress as well as inflammation that help progress AMD (Age-Related Eye Disease 
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Study Research Group, 2007). The AREDS has previously recommended a dietary 
supplementation strategy, including β-carotene, zinc, and vitamins A, C, and E (Lim, 
Mitchell, Seddon, Holz, & Wong, 2012). Currently, the supplement strategy has been 
updated to exclude β-carotene, reduce zinc, and include lutein and zeaxanthin (Age-
Related Eye Disease Study Research Group, 2007). Lutein and zeaxanthin have been 
shown to reduce reactivity of ROS in the retina, as well as reduce the effect of short-
wavelength oxidation (Age-Related Eye Disease Study Research Group, 2007). 
However, the limitation of antioxidant supplementation therapy is that it reduces 
the progression of AMD from the intermediate to late stage, as it mainly protects 
against neovascularization (Age-Related Eye Disease Study Research Group, 2007).  
As the onset of AMD has a low probability of prevention, treatment of AMD is 
even more important. Laser photocoagulation treatment is an option that treats 
choroidal neovascular lesions and yields a reduced long-term loss of visual acuity 
(Lim, Mitchell, Seddon, Holz, & Wong, 2012). However, it is rarely used as it has the 
potential to worsen immediate visual acuity, and does not prevent recurrence of 
neovascular lesion (Lim, Mitchell, Seddon, Holz, & Wong, 2012). Additionally, anti-
vascular endothelial growth factor (VEGF) therapies are administered through 
intravitreal injection to treat AMD. Because VEGF is elemental in neovascularization, 
this treatment is mainly used against the progression of AMD that leads to choroidal 
neovascularization. Ranibizumab (Lucentis. Genentech/Novartis) and bevacizumab 
(Avastin, Genentech) are administered intravitreally on a monthly basis in many 
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patients with intermediate to late-stage AMD (Lim, Mitchell, Seddon, Holz, & Wong, 
2012). While these therapies have been shown to limit loss of visual acuity in most 
patients, and even a gain of visual acuity in some patients, anti-VEGF treatment is 
focused on the progression of AMD into neovascularization, just as the AREDS 
antioxidant supplement therapy (Lim, Mitchell, Seddon, Holz, & Wong, 2012).  
Considering the finding that drusen are a result of oxidation in Crabb et al., 
2002, it may be beneficial to further understand the origin of drusen, as well as 
identify the molecular composition of drusen. One experimental design that may aid 
such research would be the use of mass spectrometry to comparatively analyze the 
compositions of hard drusen against soft drusen, as well as drusen from eye donors 
with AMD against drusen from eye donors without AMD. While such a study may be 
limited in the number of AMD donor eyes available, it would most likely help 
scientists understand the pathogenesis of AMD and create opportunities for 
treatment and prevention against the onset of early AMD.  
As the association between bilirubin and AMD is statistically significant, 
potential treatment options that target the bilirubin-biliverdin system should be 
explored. Since bilirubin has been proven to be the strongest endogenous 
antioxidant, bilirubin analogues may exhibit heightened antioxidative effects, 
relieving the retina of oxidative stress. Such therapy may even include an alteration 
in biliverdin reductase, which may be responsible for the recycling redox 
amplification system. Studying the proposed recycling mechanism in further detail 
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may allow researchers to target a specific site in which the production of bilirubin 
can be further amplified.  
The analysis of this study indicates that increased serum bilirubin levels 
protect against AMD with statistical significance. The association between bilirubin 
and AMD may aid in the understanding and research of the pathology of oxidative 
stress and its link to AMD, as well as the antioxidative effects of bilirubin and how it 
may affect macular degeneration.  
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